Document Detail

Atorvastatin: safety and tolerability.
MedLine Citation:
PMID:  20553090     Owner:  NLM     Status:  MEDLINE    
IMPORTANCE OF THE FIELD: Atorvastatin is the most widely used statin administered in a variety of settings, including primary and secondary prevention of cardiovascular events, in the elderly, in patients with chronic kidney disease and in diabetic patients. Therefore, the safety and tolerability of atorvastatin is of paramount importance. AREAS COVERED IN THIS REVIEW: We searched MEDLINE for literature published between 1997 and 2010 on the safety and tolerability of atorvastatin. We retrieved data from randomized controlled trials, meta-analyses, post-marketing studies, reports to regulatory bodies and case reports of rare adverse events. WHAT THE READER WILL GAIN: The reader will gain insight into the incidence, severity, prevention and management of the major adverse effects of atorvastatin (i.e., liver function abnormalities and muscle-related side effects) overall and in special populations. TAKE HOME MESSAGE: The existing data suggest that atorvastatin is generally well tolerated across the range of its therapeutic dosage (10 - 80 mg/day).
Vasilios G Athyros; Konstantinos Tziomalos; Asterios Karagiannis; Dimitri P Mikhailidis
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  9     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-06-17     Completed Date:  2010-09-29     Revised Date:  2010-10-20    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  667-74     Citation Subset:  IM    
Aristotle University of Thessaloniki, Hippokration Hospital, Medical School, Second Propedeutic Department of Internal Medicine, 15 Marmara St, Thessaloniki 551 32, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Heptanoic Acids / adverse effects*,  pharmacokinetics,  pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*,  pharmacokinetics,  pharmacology
Hypercholesterolemia / drug therapy*
Meta-Analysis as Topic
Product Surveillance, Postmarketing
Pyrroles / adverse effects*,  pharmacokinetics,  pharmacology
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 110862-48-1/atorvastatin
Comment In:
Expert Opin Drug Saf. 2010 Nov;9(6):1005-6; author reply 1006   [PMID:  20919802 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the...
Next Document:  Determination of a new biomarker in subjects exposed to 4,4'-methylenediphenyl diisocyanate.